A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients. University of Alabama at Birmingham, Birmingham, Alabama
- 20 January 1997
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 8 (2) , 229-242
- https://doi.org/10.1089/hum.1997.8.2-229
Abstract
The only peer-reviewed journal focused on the rapidly moving field of 3D printing and related technologies, providing comprehensive coverage of academic research and industrial and commercial developments that have applications in medicine, education, food, and architecture.This publication has 28 references indexed in Scilit:
- Reduction of erbB2 Gene-Product in Mamma Carcinoma Cell Lines by erbB2 mRNA-Specific and Tyrosine Kinase Consensus Phosphorothioate Antisense OligonucleotidesBiochemical and Biophysical Research Communications, 1994
- Taxol: A New Drug with Significant Activity as a Salvage Therapy in Advanced Epithelial Ovarian CarcinomaGynecologic Oncology, 1993
- Gene therapy for cancerTrends in Biotechnology, 1993
- Gene transfer therapy in cancerBritish Journal of Surgery, 1993
- Gene Therapy of CancerCancer Investigation, 1993
- Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancerGynecologic Oncology, 1992
- Programmed cell death: Apoptosis and oncogenesisCell, 1991
- Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the her‐2/neu oncogeneInternational Journal of Cancer, 1991
- Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogeneCell, 1988
- GROWTH FACTOR RECEPTOR TYROSINE KINASESAnnual Review of Biochemistry, 1988